Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Degboé

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Joint Bone Spine|November 6, 2020
Pre-rheumatoid arthritis and ACPA: Contribution of ACPAs in the pathogeny of pre-disease stageYannick Degboé
Joint Bone Spine|August 30, 2025
Strategies for denosumab discontinuation in postmenopausal osteoporosisYannick Degboé, Couture Guillaume
Joint Bone Spine|December 8, 2015
New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-proteinsAlain Cantagrel, Yannick Degboé
International Journal of Molecular Sciences|February 15, 2022
Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and CancerYannick Degboé, Rémy Poupot, Mary Poupot
JBMR Plus|July 17, 2023
Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar SpineMichel Laroche, Guillaume Couture, Yannick Degboé
Frontiers in Cardiovascular Medicine|July 10, 2025
The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomographyLaurence Ferrières, Michel Laroche, Yannick Degboé, et al.
Joint Bone Spine|February 19, 2019
Complex regional pain syndrome secondary to everolimus: Two casesMarion Magnol, Yannick Degboé, Guillaume Couture, et al.
RMD Open|March 9, 2017
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysisClaire Baradat, Yannick Degboé, Arnaud Constantin, et al.
Bone Reports|July 28, 2020
Effect of risedronate on bone loss at discontinuation of denosumabMichel Laroche, Guillaume Couture, Adeline Ruyssen-Witrand, et al.
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Joint Bone Spine|November 6, 2020
Pre-rheumatoid arthritis and ACPA: Contribution of ACPAs in the pathogeny of pre-disease stageYannick Degboé
Joint Bone Spine|August 30, 2025
Strategies for denosumab discontinuation in postmenopausal osteoporosisYannick Degboé, Couture Guillaume
Joint Bone Spine|December 8, 2015
New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-proteinsAlain Cantagrel, Yannick Degboé
International Journal of Molecular Sciences|February 15, 2022
Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and CancerYannick Degboé, Rémy Poupot, Mary Poupot
JBMR Plus|July 17, 2023
Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar SpineMichel Laroche, Guillaume Couture, Yannick Degboé
Frontiers in Cardiovascular Medicine|July 10, 2025
The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomographyLaurence Ferrières, Michel Laroche, Yannick Degboé, et al.
Joint Bone Spine|February 19, 2019
Complex regional pain syndrome secondary to everolimus: Two casesMarion Magnol, Yannick Degboé, Guillaume Couture, et al.
RMD Open|March 9, 2017
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysisClaire Baradat, Yannick Degboé, Arnaud Constantin, et al.
Bone Reports|July 28, 2020
Effect of risedronate on bone loss at discontinuation of denosumabMichel Laroche, Guillaume Couture, Adeline Ruyssen-Witrand, et al.
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
Pageof 4